associated with the toxic production of GM gangliosides, particularly GM2 and GM3 gangliosides, 29 in neurons that appear to underpin the neurological and psychiatric consequences of the illness. 9 Currently, over 230 disease-causing mutations of the Npc1 gene have been identified, with a subset of mutations specifically affecting the cysteine-rich luminal loop of the protein. 9 This not uncommonly results in the 'variant' biochemical phenotype, and is often associated with less severe defects in cellular LDL cholesterol trafficking than the 'classic' phenotype. 8, 30 Data from case studies suggest that this variant phenotype occurs more frequently in later-onset disease 9 and may account for the slower illness course seen in many adults.
Signs and Symptoms
Clinically, NPC is an extremely heterogeneous disease and its presentation varies greatly among patients. A review of 13 adult cases from a comprehensive study and 55 other cases of NPC examined the frequency of a number of commonly occurring clinical characteristics (see Table 1 ). 9 In adult patients, the first indication may be a motor sign such as tremor, ataxia, vertical gaze palsy or dystonia resulting in disturbances to speech, swallowing, vision, gait and fine motor control. As these symptoms may be rather subtle at onset, it is not uncommon for patients not to be aware of them; instead, family members and friends may notice slight alterations in the way the patient walks and/or talks.
By contrast, non-motor signs can also be the first notable sign in adult NPC. This includes major neuropsychiatric illnesses, often in the form of a schizophrenia-like psychotic disorder. 12 However, NPC can also present as a mood disorder and may occasionally follow childhood attention-deficit disorders. An initial psychotic disease can sometimes precede the onset of any motor symptoms by up to 10 years. 3 While most, if not all, adult patients show difficulties in vertical gaze (vertical supranuclear ophthalmoplegia) at disease onset, NPC remains heterogeneous in its clinical manifestations and the initial presentation of adult patients may be motor or neuropsychiatric in nature. 9, 12 Because of this clinical heterogeneity, adult NPC patients may present to psychiatrists as well as neurologists. Motor symptoms that occur after the initial presentation of psychiatric illness are not uncommonly and this hypothesis is also supported by a study using the NPC knockout mouse that shows significant axonal changes occurring prior to neuronal loss. 32 This may provide at least a partial explanation as to why adult patients often present with neuropsychiatric illness prior to exhibiting motor and/or cognitive impairments. Early disruption to 'macroconnectivity' (due to disrupted axonal and myelin structure) and 'microconnectivity' (due to altered synaptic structure and function)
leads to a functional disconnection that predisposes to major mental illness such as schizophrenia. This is then followed by more widespread neuronal dysfunction and loss that results in frank movement disorder and cognitive impairment. 12 The characteristic vertical gaze palsy is caused by a striking vulnerability of neurons in the rostral interstitial nucleus of the medial longitudinal fasciculus to disrupted intracellular lipid storage. 33 Ataxia results from an apparent vulnerability of cerebellar Purkinje neurons to the underlying disease process. 34, 35 Cognitive impairment, which usually involves significant memory and executive dysfunction, may result from the disruption to cellular functioning, including the deposition of neurofibrillary tangles, in major structures involved in these functions, such as the hippocampus, thalamus and higher cortex.
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Differences Between the Symptoms of Childhood and Adult Niemann-Pick Disease Type C Childhood-onset patients often present with intellectual retardation, seizures and more obvious visceral signs, such as hepatosplenomegaly, compared with adults. 39, 40 Children experience a more rapid disease course and deteriorate more quickly. [41] [42] [43] This is partially related to the nature of the mutation in the individual patient (with I1061T being a common cause of juvenile-onset illness), 8 although other factors including gender may be involved. 44 Adults generally have a slower disease progression 45 and milder splenomegaly that is often clinically missed. Niemann-Pick Disease Type C in Adulthood -A Psychiatric and Neurological Disorder prolong the lives of patients by preventing hospitalisations from falls or aspirations, which can often lead to pneumonia and death. While these therapeutic options can lessen the burden of NPC, they do not alter the underlying course of the disease or specifically target NPC.
Cholesterol-lowering Agents
As cholesterol has been thought to be an offending metabolite in NPC, a strategy that had been put forward for treating this disease was to use various cholesterol-lowering agents in an attempt to decrease intracellular cholesterol storage in patients. 46 Although certain combinations of cholestyramine, lovastatin, nicotinic acid or dimethyl sulphoxide did lower unesterified cholesterol levels in the liver and blood with minimal side effects, there has been no evidence showing any appreciable clinical benefit.
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Targeted Therapy
Substrate reduction therapy with miglustat (N-butyldeoxynojirimycin)
was recently approved for the treatment of the progressive neurological manifestations of NPC in adults, adolescents and children in a number of countries, including those of the EU. 54 This small iminosugar molecule is capable of crossing the blood-brain barrier 55 and acts as a reversible competitive inhibitor of glucosylceramide synthase, which normally catalyses the first committed step in glycosphingolipid synthesis. 56, 57 By reducing the activity of this enzyme, miglustat decreases the production of the toxic GM2 and GM3 gangliosides, 46 and it is the first approved disease-modifying therapy for NPC.
Encouraging data from pre-clinical studies in murine and feline NPC models 58 eventually led to a prospective randomised controlled clinical trial. 59 In this trial, NPC patients 12 years of age and older (n=29) were randomised to receive either miglustat at a dose of 200mg three times a day (n=20) or standard care (n=9) for 12 months, while another cohort of children less than 12 years of age (n=12) were given miglustat at a dose adjusted for body surface area. The primary end-point for all subjects was disease progression based on horizontal saccadic eye movement (HSEM) velocity.
After 12 months, patients treated with miglustat showed improvement in HSEM velocity compared with those receiving standard care. 59 The difference in improvement reached statistical significance when individuals using benzodiazepine medications, which are known to affect SEM, were excluded from both groups. Swallowing capacity and stable auditory acuity improved in treated individuals over 12 years of age and a slower deterioration in ambulatory index was observed.
Adverse events were largely mild to moderate in severity, with the most frequent negative effects associated with treatment being diarrhoea, flatulence, weight loss and abdominal pain. Two patients 12 years of age and older and one child receiving miglustat withdrew from the study due to an adverse event. Overall, miglustat was shown to stabilise neurological disease over 12 months with acceptable safety and tolerability.
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A non-controlled, open-label extension 60 of the above trial allowed patients to continue using miglustat for a further 12 months for a total of up to 24 months of treatment. These long-term data further supported findings that miglustat therapy stabilises neurological disease in NPC patients and is well tolerated in both adults and children. 60 As miglustat is currently the only targeted treatment available for NPC, a strong argument exists that it should be offered as soon as symptoms are observed and a diagnosis is made in order to minimise and arrest neuronal loss, and potentially to alter the illness course. The relatively brief clinical experience with miglustat limits any conclusions in terms of how long it may delay sentinel medical events, the need for full nursing care or death. Studies are ongoing to determine its effect on these disease end-points.
Treatments in Development
Although miglustat is currently the only agent that has been tested in humans, several drugs have shown some benefit in pre-clinical studies in animal models. The histone deacetylase inhibitor valproic acid was able to enhance neuronal differentiation and restore impaired astrocytes in defective neural stem cells in NPC1 -/-mice; this treatment reduced cholesterol levels, thereby promoting cholesterol homeostasis in the brain. 61 Imatinib therapy inhibits the proapoptotic c-Abl/p73 system and was shown to preserve
Purkinje neurons and reduce cell apoptosis in the cerebellum in addition to improving neurological symptoms and increasing survival of NPC mice. 62 Neither of these treatments has been trialled in adult NPC patients, although the use of valproic acid for mood disorders has been described in adolescent and adult patients with neuropsychiatric disease. 3, 12 Recent data demonstrated that early treatment with sterol-binding agents such as 2-hydroxy-β-cyclodextrin in NPC mice could substantially decrease cholesterol concentrations in the liver and spleen while improving both liver dysfunction and neurodegeneration. 63 Derived from the common spice turmeric, curcumin is a potent antioxidant and may also have positive effects on NPC disease. 21 Additional data from clinical studies will be required to confirm these promising outcomes and assess the long-term effects these 
